Jennifer butler
There is a huge opportunity for biotech and pharma to better address trust between patients and our industry at every level. What do you think is the biggest gap in this industry, and how would you suggest closing it? headquarters and are part of the BioHealth Capital Region community. We’re really pleased that we selected Rockville, Maryland as our U.S. The drug is FDA-approved and was originally developed by AstraZeneca/MedImmune and National Institutes of Health. footprint following Innate’s acquisition of a hairy cell leukemia medicine. I came on board in 2019 to rapidly build a commercial infrastructure and U.S. Innate is based in Marseille, France, and we celebrated our 20th-anniversary last year. We are focused on monoclonal antibodies designed to stimulate anti-tumor activity of NK cells and other cells of the innate immune system.
– a commercial-stage oncology biotech company. I am the Executive Vice President and General Manager of Innate Pharma U.S. What can you tell us about your current role and company? area with my husband, I landed my first “in-house industry job” at Emergent BioSolutions as a senior market research analyst. I was able to gain a unique perspective in working with companies and how they position themselves to raise capital, which has become invaluable throughout my career.Īfter six years of working as an analyst and consultant and relocating to the D.C. My first job was in the biotechnology group of an investor relations consulting firm, and it gave me a true education in capital markets. Right out of college, I wanted a role that gave me the pace of Wall Street and the opportunity to use my science degree. Butler has more than 20 years of strategic marketing and commercial leadership expertise along with general management experience.ġ.
![jennifer butler jennifer butler](https://static.fusionmovies.to/images/character/8kDqYcTSnh3SDl-YZii1-2AUOnL3_zt-v1TICM6U79zccHH47GsMR8EhB6w7iHEkSvkiYPlkz6z16esp8z8Lip82J_Vr2HQwW3G0ykK68Ibz-H1dT1RsPoSpkVRhgs01.jpg)
Butler also previously worked in strategic healthcare consulting and as an analyst in Equity Capital Markets at Merrill Lynch. She previously served for more than 10 years in various commercial and strategy roles with increasing responsibility at AstraZeneca/MedImmune across several therapeutic areas. Butler served as Chief Business Officer, Chief Commercial Officer and Head of US operations, responsible for global business development and commercial strategy at Tessa Therapeutics, a clinical-stage oncology company. Jennifer Butler was appointed Executive Vice President and General Manager of Innate Pharma US Inc. We’re happy to have Innate Pharma’s Jennifer Butler as our 3rd guest.
#Jennifer butler series#
“5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated.
![jennifer butler jennifer butler](https://www.uwlax.edu/User/photo/jbutlermodaff.jpg)
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S.